Ocumetics Enhances Lens Design, Delays Trials

Ocumetics Technology Corp (TSE:OTC) has released an update.

Ocumetics Technology Corp. has identified potential improvements in its accommodative intraocular lens design during internal tests, which could enhance performance and safety. The company will re-manufacture the lenses, causing a 45 to 60-day delay in its first human trials, but believes these enhancements will set new industry benchmarks.

For further insights into TSE:OTC stock, check out TipRanks’ Stock Analysis page.